Alto Neuroscience, Inc.
NYSE:ANROBiotechnology
+$0.40 today
- Market cap
- $1.04B
- Beta
- 1.25
- P/E (TTM)
- -9.8
- EPS (TTM)
- -$2.26
Volume 0.99M
Average 0.34M
ANRO Operating Cash Flow
Cash generated by the company's core business operations during the period.
Alto Neuroscience, Inc.NYSE: ANRO
Operating Cash Flow · Q1 FY2026 · quarter ended Mar 2026
Operating cash flow growth accelerates
Q1 FY2026 operating cash flow of $27.09M (cash outflow) rose 63.6% year over year, ahead of the +17.6% change in trailing-twelve-month operating cash flow. Sequentially, it rose 135.2% from the prior quarter. Over 3 fiscal years it compounded at +36.4% a year.
Context
- Operating cash flow grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether quarterly growth of +63.6% holds above the trailing-twelve-month pace of +17.6%.
Sources:Cash FlowText generated from reported figures; not investment advice.
Operating Cash Flow history
USD · from the cash flow
- Latest · FY2025
- (51.77M) USD
- Year-over-year change
- -9.2%
| Period | Period end | Operating Cash Flow | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (51.77M) | -9.2% |
| FY2024 | 2024-12-31 | (47.42M) | -41.8% |
| FY2023 | 2023-12-31 | (33.45M) | -64.0% |
| FY2022 | 2022-12-31 | (20.39M) | -120.2% |
| FY2021 | 2021-12-31 | (9.26M) | — |
Operating Cash Flow vs competitors
How ANRO compares with its peers on the latest reported figures
- Peers report in different currencies, so operating cash flow is compared through growth and share of revenue rather than absolute size.
- Its year-over-year change of +17.6% is the 5th highest of 9, against a peer median of +29.0%.
- Over three fiscal years its annual growth of +36.4% compares with a peer median of +3.8%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | $150.61M USD | +68.4% | +29.6% | — | |
| LTM Mar 2026 | $131.28M USD | +51.1% | +60.1% | — | |
| LTM Mar 2026 | $70.18M USD | +12.1% | +13.6% | 1826.7% | |
| LTM Dec 2025 | CHF 69.2M CHF | -205.1% | -3.5% | 1936.8% | |
| LTM Mar 2026 | $65.57M USD | — | +3.0% | 7115.1% | |
| LTM Mar 2026 | $62.3M USD | +17.6% | +36.4% | — | |
CTNMContineum Therapeutics, Inc. Class A Common Stock | LTM Mar 2026 | $57.17M USD | +46.0% | +40.1% | — |
| LTM Mar 2026 | $37.91M USD | -230.1% | -22.9% | 55.7% | |
| LTM Dec 2025 | $26.68M USD | — | +3.8% | — | |
| LTM Mar 2026 | $25.99M USD | -43.1% | -16.2% | — | |
| LTM Mar 2026 | $25.51M USD | +182.6% | — | 11.9% | |
| Peer median (excluding ANRO) | — | +29.0% | +3.8% | 1826.7% | |
Competitors are the stored peer set for ANRO. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Cash Flow Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Net Income | (9.19M) | (27.71M) | (36.31M) | (61.43M) | (63.24M) |
| Depreciation & Amortization | 145K | 342K | 373K | 502K | 661K |
| Deferred Income Tax | 0 | 0 | 0 | 0 | 0 |
| Stock-Based Compensation | 227K | 1.76M | 2.89M | 7.63M | 8.11M |
| Change in Working Capital | (572K) | 4.58M | (698K) | 4.06M | 33K |
| Accounts Receivables | (1.29M) | 1.16M | 325K | 0 | 0 |
| Inventory | 0 | 0 | 0 | 0 | 0 |
| Accounts Payables | 458K | 1.01M | (632K) | 516K | 221K |
| Other Working Capital | 255K | 2.42M | (391K) | 3.54M | (188K) |
| Other Non-Cash Items | 125K | 632K | 291K | 1.81M | 2.67M |
| Operating Cash Flow | (9.26M) | (20.39M) | (33.45M) | (47.42M) | (51.77M) |
| Capital Expenditures | (680K) | (732K) | (470K) | (2.08M) | (24K) |
| Acquisitions (Net) | 0 | 0 | 0 | 0 | 0 |
| Purchases of Investments | 0 | 0 | 0 | 0 | 0 |
| Sales of Investments | 0 | 0 | 0 | 0 | 0 |
| Other Investing Activities | 0 | 0 | 0 | 0 | 0 |
| Investing Cash Flow | (680K) | (732K) | (470K) | (2.08M) | (24K) |
| Debt Repayment | 0 | 9.83M | 0 | 1.25M | 9.48M |
| Common Stock Issued | 7K | 43K | 181K | 137.58M | 50.7M |
| Common Stock Repurchased | 0 | 0 | 0 | 0 | (167K) |
| Dividends Paid | 0 | 0 | 0 | 0 | 0 |
| Other Financing Activities | (205K) | (341K) | (2.05M) | (3.14M) | 67K |
| Financing Cash Flow | 31.69M | 43.79M | 68.13M | 135.69M | 60.08M |
| Effect of Forex Changes | (50K) | (24K) | (8K) | (11K) | (30K) |
| Net Change in Cash | 21.7M | 22.64M | 34.2M | 86.18M | 8.26M |
| Free Cash Flow | (9.94M) | (21.13M) | (33.92M) | (49.5M) | (51.79M) |
Alto Neuroscience, Inc.
NYSE:ANRO
Intrinsic Alpha fair value
Locked
Current Price
$25.91
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.